TY - JOUR
T1 - International Federation of Gynecology and Obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum; Estimation of survival in patients with node-positive epithelial ovarian cancer
AU - Pereira, Augusto
AU - Pérez-Medina, Tirso
AU - Magrina, Javier F.
AU - Magtibay, Paul M.
AU - Rodríguez-Tapia, Ana
AU - Peregrin, Irene
AU - Mendizabal, Elsa
AU - Ortiz-Quintana, Luís
N1 - Publisher Copyright:
Copyright © 2014 by IGCS and ESGO.
PY - 2015
Y1 - 2015
N2 - Objective: The objective of this study was to determine the survival of patients with nodepositive epithelial ovarian cancer according to the 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system. Materials and Methods: We performed a retrospective chart review. Data from all consecutive patients with node-positive epithelial ovarian cancer (stages IIIC and IV) who underwent cytoreductive surgery at the Mayo Clinic from 1996 to 2000 were reassessed to evaluate the prognostic significance of the new FIGO stages. Multivariate Cox regression was performed, and Kaplan-Meier survival curves constructed. Results: The distribution of the restaged patients was as follows: IIIA1, 23 patients (IIIA1i, 9 patients; and IIIA1ii, 14 patients); IIIA2, 3 patients; IIIB, 4; IIIC, 67 patients; IVA, 4 patients; and IVB, 15 patients. In the univariate analysis, the relative risk for positive nodes greater than 10 mm on the longer axis was 2.57 and 3.00 for patients with microscopic peritoneal disease, compared with patients with microscopic positive nodes. However, the difference was not statistically significant. Moreover, the univariate analyses revealed statistically significant differences for 2014 FIGO stages (IIIA, IIIB, IIIC, and IVA-B), anatomical sites of peritoneal metastases, and disease staged at IIIC because of the presence of omental metastases. Multivariate analysis showed that survival was higher in patients restaged to IIIA-B than in those restaged to IIIC and IV(hazard ratios, 2.75and 3.16, respectively; P = 0.002).The hazard ratio for patientswith abdominal peritoneal metastaseswas 2.76 compared with patients with pelvic peritoneal metastases (P = 0.001). Conclusions: The current 2014 FIGO staging system for ovarian cancer successfully correlates survival, anatomical location of peritoneal metastases, and extra-abdominal lymph node metastases.
AB - Objective: The objective of this study was to determine the survival of patients with nodepositive epithelial ovarian cancer according to the 2014 International Federation of Gynecology and Obstetrics (FIGO) staging system. Materials and Methods: We performed a retrospective chart review. Data from all consecutive patients with node-positive epithelial ovarian cancer (stages IIIC and IV) who underwent cytoreductive surgery at the Mayo Clinic from 1996 to 2000 were reassessed to evaluate the prognostic significance of the new FIGO stages. Multivariate Cox regression was performed, and Kaplan-Meier survival curves constructed. Results: The distribution of the restaged patients was as follows: IIIA1, 23 patients (IIIA1i, 9 patients; and IIIA1ii, 14 patients); IIIA2, 3 patients; IIIB, 4; IIIC, 67 patients; IVA, 4 patients; and IVB, 15 patients. In the univariate analysis, the relative risk for positive nodes greater than 10 mm on the longer axis was 2.57 and 3.00 for patients with microscopic peritoneal disease, compared with patients with microscopic positive nodes. However, the difference was not statistically significant. Moreover, the univariate analyses revealed statistically significant differences for 2014 FIGO stages (IIIA, IIIB, IIIC, and IVA-B), anatomical sites of peritoneal metastases, and disease staged at IIIC because of the presence of omental metastases. Multivariate analysis showed that survival was higher in patients restaged to IIIA-B than in those restaged to IIIC and IV(hazard ratios, 2.75and 3.16, respectively; P = 0.002).The hazard ratio for patientswith abdominal peritoneal metastaseswas 2.76 compared with patients with pelvic peritoneal metastases (P = 0.001). Conclusions: The current 2014 FIGO staging system for ovarian cancer successfully correlates survival, anatomical location of peritoneal metastases, and extra-abdominal lymph node metastases.
KW - 5-year overall survival
KW - FIGO staging classification
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=84927714904&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927714904&partnerID=8YFLogxK
U2 - 10.1097/IGC.0000000000000316
DO - 10.1097/IGC.0000000000000316
M3 - Article
C2 - 25405578
AN - SCOPUS:84927714904
SN - 1048-891X
VL - 25
SP - 49
EP - 54
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
IS - 1
ER -